- This clearance marks a significant advancement in glaucoma care, especially for earlier stages of the disease and across a wide spectrum of glaucoma types.
- This novel, proprietary laser-based system features a unique mechanism of action.
- Designed to deliver vibrant, high-quality visualization of eye anatomy.
- Broad commercialization is planned for 2025.
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) – BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative glaucoma surgical system, Leos™ (Laser Endoscopy Ophthalmic System) Read More